Brief: Intra-Cellular Therapies Reports Positive Phase 3 Results For Caplyta In Schizophrenia Relapse Prevention

Intra-Cellular Therapies

05/11/2024 12:04

Nov 5 (Reuters) - Intra-Cellular Therapies Inc  ITCI.O :
    * INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE TOPLINE
RESULTS IN
PHASE 3 TRIAL EVALUATING CAPLYTA FOR THE PREVENTION OF RELAPSE
IN PATIENTS WITH SCHIZOPHRENIA
    * INTRA-CELLULAR THERAPIES INC - PRIMARY ENDPOINT SHOWS
LONGER
TIME TO RELAPSE WITH LUMATEPERONE
    * INTRA-CELLULAR THERAPIES INC - 18 RELAPSES IN LUMATEPERONE
GROUP
VERSUS 44 IN PLACEBO GROUP
    * INTRA-CELLULAR THERAPIES INC - LUMATEPERONE MEETS KEY
SECONDARY
ENDPOINT IN STUDY

Source text:  ID:nGNX5wqX48 
Further company coverage:  ITCI.O 

 ((Reuters.Briefs@thomsonreuters.com;))